Infectious Disease Herpes Zoster Tracy Cross Chamberlain University NR503 NP

Infectious Disease Herpes Zoster

Tracy Cross Chamberlain University NR503 NP Dr. Rodriguez October 8, 2023

---

Introduction

Herpes Zoster, commonly known as shingles, arises from the reactivation of the varicella-zoster virus (VZV), which remains dormant in the dorsal root ganglia following a primary chickenpox infection. The virus’s latent phase can be triggered by factors that compromise or alter immune function, such as aging, significant stress, or the use of immunosuppressive medications. This reactivation results in a characteristic painful, blistering rash, typically presenting in a dermatomal pattern on one side of the body or face. Symptoms often extend beyond the rash to include fever, headache, and general malaise, contributing to the overall discomfort experienced by affected individuals (Braspenning et al., 2021). The rash associated with Herpes Zoster can last several weeks, leading to considerable pain and discomfort, which may significantly impact the quality of life.

Herpes Zoster itself is not transmitted directly between people; however, individuals who have never had chickenpox or received the varicella vaccine can contract chickenpox from coming into contact with the open sores of a Herpes Zoster rash (Braspenning et al., 2021). This indicates that while the condition is not contagious in the traditional sense, it can lead to new cases of chickenpox, particularly in unvaccinated or susceptible individuals. Complications of Herpes Zoster can be particularly severe, particularly in older adults and those with weakened immune systems. These complications may include post-herpetic neuralgia—a condition marked by persistent nerve pain long after the rash has healed—bacterial infections of the skin, vision impairment if the rash involves the eye, and other neurological issues. Antiviral treatments such as acyclovir, valacyclovir, or famciclovir are employed to reduce the severity and duration of the rash and associated pain (CDC, 2022). Pain management strategies, which may include both over-the-counter and prescription medications, are often necessary to alleviate symptoms. Vaccination with Shingrix, a shingles vaccine, is recommended for individuals aged 50 and older to help prevent Herpes Zoster and its associated complications.

Demographics and Health Determinants

Herpes Zoster predominantly affects older adults, with incidence and severity increasing significantly in those over the age of 50. Although the condition affects both men and women, some studies suggest a slightly higher incidence in females. There are no substantial racial disparities in its occurrence (CDC, 2022). While Herpes Zoster is rarely fatal, it can be severe, particularly in individuals with compromised immune systems. The morbidity associated with the condition is high due to the risk of post-herpetic neuralgia and other complications (CDC, 2022). The incidence of Herpes Zoster increases with age, with the highest rates observed in individuals over 50. The prevalence of Herpes Zoster is influenced by the age distribution of the population and the vaccination rates within the community.

Determinants of Health

Using the Healthy People 2020 (HP2020) framework, several determinants of health impact the development and spread of Herpes Zoster. Age is a primary determinant, with older adults being more susceptible due to age-related declines in immune function (CDC, 2019). Individuals with compromised immune systems, due to conditions like HIV/AIDS or immunosuppressive therapies, are also at increased risk. Health behaviors such as vaccination status play a crucial role in disease prevention. The availability and uptake of the Shingrix vaccine are directly related to the incidence of Herpes Zoster. Additionally, unhealthy behaviors such as smoking and excessive alcohol consumption can impair immune function, increasing susceptibility to infections (CDC, 2019).

Socioeconomic factors, including income and socioeconomic status, significantly influence risk. Lower-income individuals may face barriers to accessing healthcare and preventive measures like vaccinations, which can affect their risk of developing Herpes Zoster. Education levels also impact health literacy and the ability to make informed healthcare decisions, including vaccination choices (Ouwendijk et al., 2020). Access to healthcare services is a critical determinant, as the availability of vaccination services and timely medical care can influence both the prevention and management of Herpes Zoster. Effective public health policies, including vaccine recommendations and coverage, are essential in managing Herpes Zoster and minimizing its impact on the population (Sauer et al., 2021).

Epidemiological Triad

The epidemiological triad provides a comprehensive framework for understanding Herpes Zoster. Host factors include age, immune status, and gender. Older individuals, especially those over fifty, are more vulnerable due to immune system changes associated with aging. Immunocompromised individuals, such as those with HIV/AIDS or on immunosuppressive therapies, are also at increased risk. Gender may play a minor role, with some studies suggesting a slightly higher incidence in females (Kain et al., 2023).

The agent in the triad is the varicella-zoster virus (VZV). After causing chickenpox, VZV remains dormant in the nerve cells and can reactivate later in life to cause Herpes Zoster. Reactivation is influenced by various factors, including stress and age-related immune system changes (Kain et al., 2023). Environmental factors that impact Herpes Zoster include climate, which may affect the seasonality of outbreaks, and housing conditions that could influence transmission rates. Access to healthcare, particularly vaccination and timely treatment, is crucial for managing the disease and preventing its spread (Kain et al., 2023). The interplay between demographic factors, VZV presence, and environmental conditions highlights the complexity of Herpes Zoster dynamics.

Role of the Nurse Practitioner (NP)

Nurse Practitioners (NPs) play a vital role in managing infectious diseases such as Herpes Zoster. According to the American Association of Nurse Practitioners (AANP), NPs provide comprehensive healthcare services that include health promotion, disease prevention, assessment, diagnosis, and treatment. NPs are involved in disease surveillance, identifying patterns, outbreaks, and unusual occurrences within their patient populations (CDC, 2019). They focus on prevention by educating patients and communities about strategies to prevent infections, such as vaccination, hand hygiene, and lifestyle changes. Assessing patients' immunization status and administering vaccines as needed are key responsibilities.

NPs are adept at early detection and diagnosis, ordering necessary diagnostic tests and initiating timely treatments to control disease spread. They often collaborate with infectious disease specialists for complex cases and manage patient care by ensuring appropriate treatment and addressing complications with the help of multidisciplinary teams (CDC, 2019). NPs are also responsible for adhering to legal and ethical standards, including reporting notifiable diseases to public health authorities. They collect and analyze patient data to inform evidence-based decisions and public health strategies. Ongoing follow-up care, including monitoring treatment response and managing side effects, is also part of their role (Braspenning et al., 2021).

In practice, NPs apply evidence-based models such as the “Clinical Nurse Leader” model or the “Promotion of Health and Management of Illness” model to guide their care delivery. These models emphasize the integration of research evidence, clinical expertise, and patient preferences to ensure effective management of infectious diseases like Herpes Zoster (Bender et al., 2019). By leveraging evidence-based guidelines, NPs contribute to improved patient outcomes and effective disease control within their communities.

References

Bender, P., Harris, J. L., Hites, L., LaPointe, R. J., Murphy, E. A., Roussel, L., Spiva, L., Stanley, J. M., Thomas, P. L., & Williams, M. (2019). Advancing the clinical nurse leader model through academic-practice-policy partnership. Nursing Outlook, 67(4), 345-353. https://doi.org/10.1016/j.outlook.2019.02.007

Braspenning, Verjans, G. M. G., Mehraban, T., Messaoudi, I., Depledge, D. P., & Ouwendijk, W. J. (2021). The architecture of the simian varicella virus transcriptome. PLoS Pathogens, 17(11), e1010084-e1010084. https://doi.org/10.1371/journal.ppat.1010084

Centers for Disease Control and Prevention. (2022). Shingles (Herpes Zoster). https://www.cdc.gov/shingles/index.html

Centers for Disease Control and Prevention. (2019). Healthy People 2020. https://www.cdc.gov/dhdsp/hp2020.htm#Pathogens

Kain, A., Tizek, L., Wecker, H., Wallnöfer, F., Biedermann, T., & Zink, A. (2023). Evaluating public interest in herpes zoster in Germany by leveraging the internet: a retrospective search data analysis. BMC Public Health, 23(1), 1546. https://doi.org/10.1186/s12889-023-1010084

Ouwendijk, W. J., Depledge, D. P., Labchan, R., Lenac, R. T., Stipan, J., Breuer, J., Arun, V., Verjans, G. M. G. M., & Tomohiko, S. (2020). Varicella-zoster virus VLT-ORF63 fusion transcript induces broad viral gene expression during reactivation. Journal of Virology, 94(6), e01548-19. https://doi.org/10.1128/JVI